Safety and Effectiveness of Banked Cord Blood or Bone Marrow Stem Cells in Children With Cerebral Palsy (CP).

Exclusion Criteria

• •1. Known history of:
• •* Intractable seizures
• •* Traumatic brain injury
• •* Genetic disorder (as demonstrated by newborn screening or genetic diagnostic testing)
• •* Recently treated or current infection
• •* Renal insufficiency or altered renal function (as defined by serum creatinine \> 1.5 mg/dl at screening)
• •* Hepatic disease or altered liver function (as defined by SGPT \> 150 U/L \[non-contusion related\], and/or T. Bilirubin \>1.3 mg/dL at screening)
• •* HIV+ (as demonstrated by positive blood test)
• •* Immunosuppression (as defined by WBC \<3,000 cells/ml at screening)
• •* Infectious related neurological injury
• •* Sensitivity to Ethylene Oxide (EtO) \[found in fumigants and disinfectants\]
• •2. If Athetoid CP diagnosis, other etiologies such as degenerative, mitochondrial, and metabolic disorders must be excluded, and the outcome assessments must be able to be conducted to assess for potential treatment effects
• •3. Normal brain MRI
• •4. Evidence of acute illness at the time of infusion, such as, but not limited to, fever (temperature \> 37.5 C), vomiting, diarrhea, wheezing or crackles
• •5. Progressing neurological disease (as defined by Batten Disease, Leukodystrophies, Metabolic disorders, Mitochondrial disorders, Neurotransmitter disorders)
• •6. Microcephaly, macrocephaly, cortical malformations, genetic disorders of dysgenesis brain malformations due to infection or metabolic disorders
• •7. Pulmonary disease requiring ventilator support
• •8. If hUCB candidate, banked cord cells totaling \<10 million/kg
• •9. If hUCB candidate, any positive maternal infectious disease test (Hepatitis A, Hepatitis B, HIV 1, HIV 2, HTLV 1, HTLV 2, and Syphilis)
• •10. If hUCB candidate, cord blood sample contamination
• •11. Participation in a concurrent intervention study
• •12. Unwillingness to return for follow-up visits
• •13. Contraindications to MRI
• •14. Any patient that the investigators feel in their opinion the study intervention is unlikely to benefit the patient will be a screen failure.
• •15. Any patients who are currently or has previously been enrolled in a clinical stem cell study.